MedTrace Logo

Vercise Implantable Stimulator for Treating Parkinson's Disease

NCT01221948 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-02-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to document patient outcomes, including effectiveness, safety, and health economic data, for the Boston Scientific implantable deep brain stimulation (DBS) Vercise™ system for bilateral stimulation of the subthalamic nucleus (STN) in the treatment of moderate to severe idiopathic Parkinson's Disease (PD).

Conditions

  • Idiopathic Parkinson's Disease

Interventions

DEVICE

Deep Brain Stimulation

Rechargeable Deep Brain Stimulation System

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Lars Timmermann, M.D. · Universitätsklinikum Köln

  • François Alesch, M.D. · Allgemeines Krankenhaus AKH, Vienna, Austria

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-05-31
Completion
2018-06-01

Countries

  • Austria
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01221948 on ClinicalTrials.gov